Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response

Cell Death and Differentiation

Volumn 21, Issue 9, 2014, Pages 1409-1418

  Nair, B C ^a   Krishnan, S R ^a   Sareddy, G R ^a   Mann, M ^a   Xu, B ^b   Natarajan, M ^a   Hasty, P ^a   Brann, D ^c   Tekmal, R R ^a   Vadlamudi, R K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b S Research Institute PO Box 55305   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COREPRESSOR PROTEIN; PELP1 PROTEIN, HUMAN; PROTEIN P53; TRANSCRIPTION FACTOR;

DNA DAMAGE; HUMAN; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; DNA DAMAGE; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905921690     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.55     Document Type: Article

References (45)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
3. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
4. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-312.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
6. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010; 2: a000935.
7. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
8. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 13777-13782.
9. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
10. Appella E, Anderson CW. Signaling to p53: breaking the posttranslational modification code. Pathol Biol (Paris) 2000; 48: 227-245.
11. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
12. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 2009; 1: a000950.
13. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006; 13: 951-961.
14. Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 2005; 331: 778-785.
15. Mann M, Zou Y, Chen Y, Brann D, Vadlamudi R. PELP1 oncogenic functions involve alternative splicing via PRMT6. Mol Oncol 2013; 13: 10.
16. Girard BJ, Daniel AR, Lange CA, Ostrander JH. PELP1: a review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol 2014; 382: 642-651.
17. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007; 5: e004.
18. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P et al. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 2014; e-pub ahead of print 27 January 2014; doi:10.1038/onc.2013.579.
19. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD et al. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun 2013; 4: 1923.
20. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004; 64: 6416-6423.
21. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A et al. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 2001; 276: 38272-38279.
22. Rosendorff A, Sakakibara S, Lu S, Kieff E, Xuan Y, DiBacco A et al. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci USA 2006; 103: 5308-5313.
23. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005; 121: 873-885.
24. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schule R et al. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 2010; 11: 438-444.
25. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR et al. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 2010; 70: 7166-7175.
26. Finkbeiner E, Haindl M, Muller S. The SUMO system controls nucleolar partitioning of a novel mammalian ribosome biogenesis complex. EMBO J 2011; 30: 1067-1078.
27. Singh RR, Gururaj AE, Vadlamudi RK, Kumar R. 9-Cis-retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway. J Biol Chem 2006; 281: 15394-15404.
28. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E, Anderson CW. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol 1992; 12: 5041-5049.
29. Traven A, Heierhorst J. SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA-damage-response proteins. Bioessays 2005; 27: 397-407.
30. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-1166.
31. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
32. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000; 19: 3078-3085.
33. Scata KA, El-Deiry WS. p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol 2007; 608: 70-86.
34. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
35. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005; 41: 2485-2501.
36. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-330.
37. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992; 257: 212-214.
38. Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M. c-Myc-dependent etoposideinduced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem 2006; 98: 1597-1614.
39. Guerra L, Albihn A, Tronnersjo S, Yan Q, Guidi R, Stenerlow B et al. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS One 2010; 5: e8924.
40. Tyagi S, Herr W. E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases. EMBO J 2009; 28: 3185-3195.
41. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21: 43-48.
42. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
43. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, WangWet al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 2011; 108: 14240-14245.
44. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209-218.
45. Chen Y, Zhang L, Jones KA. SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicing. Genes Dev 2011; 25: 701-716.